medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Número 4

<< Anterior Siguiente >>

Ann Hepatol 2017; 16 (4)


Hepatitis C Virus Infection and Risk of Venous Thromboembolism: A Systematic Review and Meta-Analysis

Wijarnpreecha K, Thongprayoon C, Panjawatanan P, Ungprasert P

Idioma: Ingles.
Referencias bibliográficas: 35
Paginas: 514-520
Archivo PDF: 149.40 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42. doi: 10.1002/hep.26141.

  2. Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud- Ratti V, Yamamoto AM, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l’Hepatite C. Medicine (Baltimore) 2000; 79: 47-56.

  3. El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002; 36: 1439-45. doi: 10.1053/ jhep.2002.37191.

  4. Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995; 123: 615-20.

  5. Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 2008; 28: 370-2. doi: 10.1161/ATVBAHA.108.162545.

  6. Dabbagh O, Oza A, Prakash S, Sunna R, Saettele TM. Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease. Chest 2010; 137: 1145-9. doi: 10.1378/chest.09-2177.

  7. Goldhaber SZ. Risk factors for venous thromboembolism. J Am Coll Cardiol 2010; 56: 1-7. doi: 10.1016/ j.jacc.2010.01.057.

  8. Ocak G, Vossen CY, Verduijn M, Dekker FW, Rosendaal FR, Cannegieter SC, Lijfering WM. Risk of venous thrombosis in patients with major illnesses: results from the MEGA study. J Thromb Haemost 2013; 11: 116-23. doi: 10.1111/jth.12043.

  9. Ungprasert P, Srivali N, Wijarnpreecha K, Charoenpong P, Knight EL. Non-steroidal anti-inflammatory drugs and risk of venous thromboembolism: a systematic review and metaanalysis. Rheumatology (Oxford) 2015; 54: 736-42. doi: 10.1093/rheumatology/keu408.

  10. Saghazadeh A, Rezaei N. Inflammation as a cause of venous thromboembolism. Crit Rev Oncol Hematol 2016; 99: 272-85. doi: 10.1016/j.critrevonc.2016.01.007.

  11. Xu J, Lupu F, Esmon CT. Inflammation, innate immunity and blood coagulation. Hamostaseologie 2010; 30: 5-6, 8-9.

  12. Alkim H, Koksal AR, Boga S, Sen I, Alkim C. Etiopathogenesis, Prevention, and Treatment of Thromboembolism in Inflammatory Bowel Disease. Clin Appl Thromb Hemost 2016. doi: 10.1177/1076029616632906.

  13. Avina-Zubieta JA, Vostretsova K, De Vera MA, Sayre EC, Choi HK. The risk of pulmonary embolism and deep venous thrombosis in systemic lupus erythematosus: A general population- based study. Semin Arthritis Rheum 2015; 45: 195- 201. doi: 10.1016/j.semarthrit.2015.05.008.

  14. Ungprasert P, Sanguankeo A. Risk of venous thromboembolism in patients with idiopathic inflammatory myositis: a systematic review and meta-analysis. Rheumatol Int 2014; 34: 1455-8. doi: 10.1007/s00296-014-3023-1.

  15. Ungprasert P, Sanguankeo A, Upala S, Suksaranjit P. Psoriasis and risk of venous thromboembolism: a systematic re view and meta-analysis. QJM 2014; 107: 793-7. doi: 10.1093/qjmed/hcu073.

  16. Ungprasert P, Srivali N, Spanuchart I, Thongprayoon C, Knight EL. Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 2014; 33: 297-304. doi: 10.1007/s10067- 014-2492-7.

  17. Ungprasert P, Wijarnpreecha K, Tanratana P. Risk of venous thromboembolism in patients with celiac disease: A systematic review and meta-analysis. J Gastroenterol Hepatol 2015. doi: 10.1111/jgh.13282.

  18. Ahmed S MV, Vendeti N, Ann Phang K, Su Y, Kim H, Mast T, Nancy S. Risk of venous thromboembolism (VTE) in patients with chronic hepatitis C (CHC). Pharmacoepidemiol Drug Saf 2012; 21: 94.

  19. Best MJ, Buller LT, Klika AK, Barsoum WK. Increase in perioperative complications following primary total hip and knee arthroplasty in patients with hepatitis C without cirrhosis. J Arthroplasty 2015; 30: 663-8. doi: 10.1016/ j.arth.2014.11.013.

  20. Enger C, Forssen UM, Bennett D, Theodore D, Shantakumar S, McAfee A. Thromboembolic events among patients with hepatitis C virus infection and cirrhosis: a matched-cohort study. Adv Ther 2014; 31: 891-903. doi: 10.1007/s12325- 014-0138-4.

  21. Galli L, Gerdes VE, Guasti L, Squizzato A. Thrombosis Associated with Viral Hepatitis. J Clin Transl Hepatol 2014; 2: 234-9. doi: 10.14218/JCTH.2014.00031.

  22. Wang CC, Chang CT, Lin CL, Lin IC, Kao CH. Hepatitis C Virus Infection Associated With an Increased Risk of Deep Vein Thrombosis: A Population-Based Cohort Study. Medicine (Baltimore) 2015; 94: e1585. doi: 10.1097/ MD.0000000000001585.

  23. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-5. doi: 10.1007/s10654-010-9491-z.

  24. Herzog R, Alvarez-Pasquin MJ, Diaz C, Del Barrio JL, Estrada JM, Gil A. Are healthcare workers’ intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. BMC Public Health 2013; 13: 154. doi: 10.1186/ 1471-2458-13-154.

  25. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.

  26. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60. doi: 10.1136/bmj.327.7414.557.

  27. Ambrosino P, Tarantino L, Criscuolo L, Nasto A, Celentano A, Di Minno MN. The risk of venous thromboembolism in patients with hepatitis C. A systematic review and meta-analysis. Thromb Haemost 2016; 116: 958-966. doi: 10.1160/ TH16-03-0185.

  28. RostamiJalilian M. OGM, Kassaeian N. Relationship of Hepatitis B and C with Deep Vein Thrombosis in I.V Drug Abusers. J Mil Med 2006; 8: 78-81.

  29. El Bokl MA, Shawky A, Riad GS, Abdel Fattah HS, Shalaby H, Nady A, Khattab D. Procoagulant versus anticoagulant factors in cirrhotic patients. Arab J Gastroenterol 2014; 15: 123-9. doi: 10.1016/j.ajg.2014.08.003.

  30. Montecucco F, Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) 2009; 48: 11-22. doi: 10.1093/rheumatology/ken395.

  31. Samad F, Ruf W. Inflammation, obesity, and thrombosis. Blood 2013; 122: 3415-22. doi: 10.1182/blood-2013-05- 427708.

  32. Bartoloni E, Shoenfeld Y, Gerli R. Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin. Arthritis Care Res (Hoboken) 2011; 63: 178-83. doi: 10.1002/acr.20322.

  33. Biasillo G, Leo M, Della Bona R, Biasucci LM. Inflammatory biomarkers and coronary heart disease: from bench to bedside and back. Intern Emerg Med 2010; 5: 225-33. doi: 10.1007/s11739-010-0361-1.

  34. Ramos-Casals M, Munoz S, Medina F, Jara LJ, Rosas J, Calvo- Alen J, Brito-Zeron P, et al. Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol 2009; 36: 1442-8. doi: 10.3899/jrheum.080874.

  35. Gill K, Ghazinian H, Manch R, Gish R. Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol Int 2016; 10: 415-23. doi: 10.1007/s12072-015-9684-3.




2020     |     www.medigraphic.com